2219362-41-9
Chemical Structure
GS-9822
- CAS No.: 2219362-41-9
- Formula:C36H39ClN4O4S
- Molecular Weight:659.24
IUPAC Name: (S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid
InChIKey: RRMWWVMCCINVHZ-YTTGMZPUSA-N
SMILES: CC(C)(C)O[C@@H](C1=C(C)C=C(N=C(C2=CC=C3C(C(C4CCN(C5COC5)CC4)=NN3C)=C2)S6)C6=C1C7=CC=C(Cl)C=C7)C(O)=O
Biological Activity: GS-9822 is a potent antivira agent with nanomolar activity against wild-type HIV-1 viruses. GS-9822 potently inhibits the LEDGF/p75-integrase interaction with an IC50 of 0.07 μM. GS-9822 has high in vitro metabolic stability and favorable oral pharmacokinetic profiles with low systemic clearance in rats, dogs, and monkeys[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
GS-9822 | GS-9822 is a potent antivira agent with nanomolar activity against wild-type HIV-1 viruses. GS-9822 potently inhibits the LEDGF/p75-integrase interaction with an IC50 of 0.07 μM. GS-9822 has high in vitro metabolic stability and favorable oral pharmacokinetic profiles with low systemic clearance in rats, dogs, and monkeys. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
